08. Respiratory microbiome in IPF: Pathogenesis, Progression and Exacerbations.

Philip Molyneaux.
Royal Brompton Hospital, London, UK


[tabs] [tab title=Presentació  icon=”desktop” icon_color=”#87B1B5″]<
[/tab] [tab title=Abstract icon=”book” icon_color=”#87B1B5″]

Respiratory microbiome in IPF: Pathogenesis, Progression and Exacerbations


Philip Molyneaux.
Royal Brompton Hospital, London, UK.

The recent characterization of the respiratory microbiome in idiopathic pulmonary fibrosis (IPF) has suggested that an increased bacterial burden, and presence of specific organisms, could drive disease progression. This strengthens the epidemiological argument that environmental factors may be integral to the pathogenesis of IPF in genetically susceptible individuals. However, there remain a number of unanswered questions regarding the role of the microbiome in IPF including the effect of the MUC5B polymorphism and the optimal sampling modality to study a parenchymal disease process.

We will review the current understanding of the microbiome in fibrotic lung disease, and explore the evidence supporting the role of the microbiome in the pathogenesis and progression of IPF. We will then discuss how an understanding of the microbiome may help us to gain further insights into currently “non-infective” acute exacerbations of IPF.

[/tab] [tab title=Currículum Vitae icon=”briefcase” icon_color=”#87B1B5″]

Philip Molyneaux. Qualified from Guy’s, King’s and St Thomas’ School of Medicine in 2004, where he completed an intercalated BSc. in Molecular Genetics. He undertook his clinical training at Guy’s and St Thomas’ and went on to attained an NIHR Academic Clinical Fellow position in Respiratory medicine at Imperial College. He spent the next two years training at St Mary’s Hospital and working with Professors Cookson, Moffatt and Johnston studying the respiratory microbiome in COPD.

Moving to the Royal Brompton Hospital he went on to complete a PhD examining the host response and microbial flora in Idiopathic Pulmonary Fibrosis (IPF) as part of the Prospective Study of Fibrosis In the Lung Endpoints (PROFILE) study with Dr Toby Maher. His ongoing work concentrates on delineating the host microbe interaction in fibrotic lung disease.


[/tab] [/tabs]

Choose your language